Intuitive Surgical, Inc. $ISRG Stock Purchased by Foster Victor Wealth Advisors LLC

Foster Victor Wealth Advisors LLC increased its position in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 14.7% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 22,749 shares of the medical equipment provider’s stock after buying an additional 2,915 shares during the period. Foster Victor Wealth Advisors LLC’s holdings in Intuitive Surgical were worth $9,855,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the company. Plato Investment Management Ltd bought a new stake in Intuitive Surgical in the second quarter worth $4,315,000. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in Intuitive Surgical during the second quarter valued at $14,316,000. Hikari Power Ltd purchased a new stake in Intuitive Surgical during the second quarter valued at $5,619,000. Nykredit A S bought a new position in Intuitive Surgical during the second quarter valued at $48,464,000. Finally, NewEdge Advisors LLC lifted its position in Intuitive Surgical by 19.1% during the second quarter. NewEdge Advisors LLC now owns 50,825 shares of the medical equipment provider’s stock valued at $20,212,000 after purchasing an additional 8,142 shares during the last quarter. 83.64% of the stock is currently owned by hedge funds and other institutional investors.

Intuitive Surgical Stock Performance

NASDAQ ISRG opened at $428.12 on Thursday. The company has a market cap of $151.25 billion, a P/E ratio of 49.10, a P/E/G ratio of 3.30 and a beta of 1.46. The business’s 50 day moving average price is $393.50 and its 200-day moving average price is $408.89. Intuitive Surgical, Inc. has a fifty-two week low of $328.57 and a fifty-two week high of $603.88.

Intuitive Surgical (NASDAQ:ISRG) last released its quarterly earnings results on Tuesday, October 20th. The medical equipment provider reported $3.00 earnings per share for the quarter, beating the consensus estimate of $2.65 by $0.35. The company had revenue of $3.05 billion for the quarter, compared to analyst estimates of $2.91 billion. Intuitive Surgical had a return on equity of 17.70% and a net margin of 25.54%. Intuitive Surgical’s quarterly revenue was up 21.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.40 EPS. As a group, equities analysts predict that Intuitive Surgical, Inc. will post 8.87 EPS for the current year.

Insider Buying and Selling at Intuitive Surgical

In other news, Director Gary S. Guthart sold 10,000 shares of the firm’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $400.00, for a total value of $4,000,000.00. Following the completion of the sale, the director owned 1,245,679 shares in the company, valued at approximately $498,271,600. This trade represents a 0.80% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Fredrik Widman sold 1,089 shares of Intuitive Surgical stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $374.44, for a total transaction of $407,765.16. Following the transaction, the vice president directly owned 1,026 shares of the company’s stock, valued at approximately $384,175.44. This represents a 51.49% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 12,370 shares of company stock valued at $4,891,989. Insiders own 0.60% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have commented on ISRG. Leerink Partners set a $503.00 price objective on shares of Intuitive Surgical and gave the stock an “outperform” rating in a research note on Wednesday. Weiss Ratings restated a “hold (c)” rating on shares of Intuitive Surgical in a report on Friday, August 14th. JPMorgan Chase & Co. upped their target price on shares of Intuitive Surgical from $450.00 to $475.00 and gave the company an “overweight” rating in a research report on Wednesday. Royal Bank Of Canada lowered their price target on shares of Intuitive Surgical from $575.00 to $550.00 and set an “outperform” rating for the company in a report on Wednesday. Finally, Mizuho lowered their price target on shares of Intuitive Surgical from $415.00 to $400.00 and set a “neutral” rating for the company in a report on Wednesday. Twenty-five research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $500.13.

More Intuitive Surgical News

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: Q3 revenue increased 21.7% year over year to $3.05 billion, surpassing the $2.91 billion consensus estimate, while adjusted earnings of $3.00 per share exceeded expectations of approximately $2.65. Intuitive Surgical Q3 Earnings and Revenues Top Estimates
• Positive Sentiment: Underlying demand remained healthy: worldwide procedures grew approximately 15%, including about 14% growth in da Vinci procedures and 31% growth in Ion procedures. System placements also rose to 546 from 427 a year earlier. Intuitive Announces Third Quarter Earnings
• Positive Sentiment: Several analysts maintained bullish views or raised targets following the report, including JPMorgan, which lifted its target to $475 and kept an Overweight rating, while Bank of America reiterated Buy with a $470 target. Intuitive Surgical Buy Rating Reaffirmed

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops and manufactures robotic-assisted systems and related technologies for minimally invasive surgery. Its products are designed to help surgeons perform procedures through small incisions while providing enhanced visualization, precision and control. The company’s primary platform is the da Vinci Surgical System, which is used across a range of specialties, including urology, gynecology, general surgery, cardiothoracic surgery and other procedures.

The company also offers the Ion endoluminal system, which is designed to support minimally invasive lung biopsy procedures.